Shanghai Kaibao Pharmaceutical CO.,Ltd (SHE:300039)

Market Cap	6.09B -12.7%
Revenue (ttm)	1.04B -26.0%
Net Income	259.16M -30.2%
EPS	0.25 -30.2%
Shares Out	1.05B
PE Ratio	23.50
Forward PE	n/a
Dividend	0.06 (1.05%)
Ex-Dividend Date	Nov 27, 2025

Volume	9,523,230
Average Volume	13,645,772
Open	5.77
Previous Close	5.73
Day's Range	5.70 - 5.82
52-Week Range	5.59 - 7.03
Beta	0.39
RSI	42.55
Earnings Date	Apr 28, 2026

About SHE:300039

Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and respiratory infections; and Phlegm-Heat Clearing Capsules to clear heat, resolve phlegm, and detoxifying. It also provides liver-protecting products, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 1,225
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300039

Financial Performance

In 2025, SHE:300039's revenue was 1.15 billion, a decrease of -21.76% compared to the previous year's 1.47 billion. Earnings were 278.58 million, a decrease of -25.83%.